RESEARCH TRIANGLE PARK, N.C. — Tranzyme Pharma is amending its investigational new drug application with the Food and Drug Administration for its candidate TZP-101 in order to possibly treat a second condition.
Tranzyme said Thursday it wants to utilize TZP-101 as a treatment for diabetic patients who suffer from gastroparesis, which is a disorder that delays emptying of the stomach. It can exist in acute and chronic forms, the company said.
TZP-101 was originally intended to treat ileus, which is a blockage of the bowels.
Tranzyme noted that the most potent drug to treat gastroparesis, Propulsid, was withdrawn in 2000 due to adverse side effects. It had $1 billion in global sales, Tranzyme said in a statement.
Tranzyme hopes to begin Phase II testing of TZP-101 in 2007.